Antibe Therapeutics Inc (ATE)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Antibe Therapeutics Inc (ATE) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011249
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Antibe Therapeutics Inc (Antibe) is a biotechnology company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercialize novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen derivative for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis; ATB-352 for gout, dysmenorrhea, dental pain, post-surgical pain, and ATB-340 for chronic prevention of cardiovascular disease and cancer chemoprevention. Antibe also offers regenerative medical devices, which include CGX-227, CGX-443 and CGX-276 which are indicated for oral and maxillofacial surgery. The company distributes its products across Europe, the Americas, the Middle East and Asia.Antibe is headquartered in Toronto, Ontario, Canada.

Antibe Therapeutics Inc (ATE) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Antibe Therapeutics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Antibe Therapeutics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Antibe Therapeutics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Antibe Therapeutics Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Antibe Therapeutics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Antibe Therapeutics Inc, Medical Equipment, Deal Details 10
Partnerships 10
Antibe Therapeutics Enters into Licensing Agreement with Induce Biologics 10
Equity Offering 11
Antibe Therapeutics Raises USD3 Million in Public Offering of Units 11
Antibe Therapeutics Raises USD2 Million in Private Placement of Units 13
Antibe Therapeutics Raises USD0.8 Million in First Tranche of Private Placement of Units 14
Acquisition 16
Antibe Therapeutics Acquires Remaining 15% Stake in Citagenix for USD0.4 Million 16
Antibe Therapeutics Acquires 85% Stake in Citagenix 17
Antibe Therapeutics Inc – Key Competitors 18
Antibe Therapeutics Inc – Key Employees 19
Antibe Therapeutics Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Strategy And Business Planning 21
Oct 11, 2016: Antibe Therapeutics Announces Launch of Strategic Growth Initiative in the U.S. Market for Dental Biologics 21
Financial Announcements 22
Nov 28, 2017: Antibe Therapeutics Reports Q2 2018 Interim Financial and Operating Results and Provides Corporate Update 22
Aug 29, 2017: Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results 23
Mar 01, 2017: Antibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results 24
Nov 29, 2016: Antibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results 25
Corporate Communications 26
Jul 19, 2016: Antibe Therapeutics Announces the Appointment of New Board Member 26
Product News 27
Aug 16, 2016: Antibe Therapeutics launches Neomem FlexPlus barrier membrane for oral surgery 27
Other Significant Developments 28
Oct 26, 2017: Antibe Therapeutics Announces Key US Distribution Partnership for Its Subsidiary, Citagenix 28
Aug 29, 2016: Antibe Therapeutics Reports Q1 2017 Interim Financial and Operating Results 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Antibe Therapeutics Inc, Medical Equipment, Key Facts, 2017 2
Antibe Therapeutics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Antibe Therapeutics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Antibe Therapeutics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Antibe Therapeutics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Antibe Therapeutics Inc, Deals By Market, 2011 to YTD 2017 8
Antibe Therapeutics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Antibe Therapeutics Enters into Licensing Agreement with Induce Biologics 10
Antibe Therapeutics Raises USD3 Million in Public Offering of Units 11
Antibe Therapeutics Raises USD2 Million in Private Placement of Units 13
Antibe Therapeutics Raises USD0.8 Million in First Tranche of Private Placement of Units 14
Antibe Therapeutics Acquires Remaining 15% Stake in Citagenix for USD0.4 Million 16
Antibe Therapeutics Acquires 85% Stake in Citagenix 17
Antibe Therapeutics Inc, Key Competitors 18
Antibe Therapeutics Inc, Key Employees 19
Antibe Therapeutics Inc, Subsidiaries 20

★海外企業調査レポート[Antibe Therapeutics Inc (ATE)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Seikagaku Corp (4548):企業の財務・戦略的SWOT分析
    Summary Seikagaku Corp (Seikagaku) is a manufacturer and supplier of pharmaceuticals and medical devices. The company offers products such as pharmaceuticals and medical devices, bulk products, endotoxin-detecting reagents and oral care products. It also manufactures and markets pharmaceutical produ …
  • Qsc AG (QSC):企業の財務・戦略的SWOT分析
    Summary Qsc AG (Qsc) is a telecommunication company that provides integrated telecommunication and managed services. The company offers services such as cloud and IT outsourcing, Internet of Things services, sap services and consulting, broadband and network services, and colocation services. Its cl …
  • Sophiris Bio Inc (SPHS):製薬・医療:M&Aディール及び事業提携情報
    Summary Sophiris Bio Inc (Sophiris) is a clinical stage bio-pharmaceutical company, which focuses on developing products for the treatment of urological diseases. Sophiris lead drug candidate, PRX302 is under late stage development for the treatment of lower urinary tract symptoms of benign prostati …
  • Indeck Energy Services Inc:企業の戦略的SWOT分析
    Indeck Energy Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • PT. Bank Rakyat Indonesia (Persero) Tbk.:戦略・SWOT・企業財務分析
    PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report Summary PT. Bank Rakyat Indonesia (Persero) Tbk. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Host Hotels & Resorts, Inc.:企業の戦略・SWOT・財務情報
    Host Hotels & Resorts, Inc. - Strategy, SWOT and Corporate Finance Report Summary Host Hotels & Resorts, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Chimerix Inc (CMRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Chimerix Inc (Chimerix) is a biopharmaceutical company that develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s brincidofovir is an oral nucleotide analog to treat dsDNA viruses, adenovirus, cytomegalovirus, BK virus and herpes simplex viruses. It als …
  • Bonterra Energy Corp (BNE):企業の財務・戦略的SWOT分析
    Bonterra Energy Corp (BNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • People’s Bank:企業の戦略・SWOT・財務情報
    People's Bank - Strategy, SWOT and Corporate Finance Report Summary People's Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Electricity Generating Public Co Ltd (EGCO):電力:M&Aディール及び事業提携情報
    Summary Electricity Generating Public Co Ltd (EGCO), a subsidiary of Electricity Generating Authority of Thailand (EGAT), is an energy utility. It produces electricity from natural gas, coal, biomass, waste, hydro, solar, wind, and geothermal sources. Through interests in independent power producer …
  • The Reject Shop Ltd (TRS):企業の財務・戦略的SWOT分析
    The Reject Shop Ltd (TRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Synthon Holdings BV:企業の戦略的SWOT分析
    Synthon Holdings BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Open Text Corporation (OTEX):企業の財務・戦略的SWOT分析
    Open Text Corporation (OTEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • REC Silicon ASA (REC)-エネルギー分野:企業M&A・提携分析
    Summary REC Silicon ASA (REC Silicon), formerly Renewable Energy Corporation ASA, produces and supplies advanced silicon materials. It offers solar grade polysilicon, electronic grade polysilicon, and silicon gases. Its products find application in the solar and electronics industries in the product …
  • Dana Brevini Spa:企業の戦略・SWOT・財務分析
    Dana Brevini Spa - Strategy, SWOT and Corporate Finance Report Summary Dana Brevini Spa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Nordic Investment Bank:電力:M&Aディール及び事業提携情報
    Summary Nordic Investment Bank (NIB) is a banking and financial service provider that offers loans and capital market solutions. The company offers loan products such as project and structured loans, corporate loans, municipality’s loans, environmental loans, sovereign loans, and other loans. It als …
  • Ultrapar Participacoes SA (UGPA3):企業の財務・戦略的SWOT分析
    Ultrapar Participacoes SA (UGPA3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Clovis Oncology Inc (CLVS):製薬・医療:M&Aディール及び事業提携情報
    Summary Clovis Oncology Inc (Clovis) is a biopharmaceutical company that acquires, develops and commercializes new anti-cancer agents. The company's development programs are targeted at specific cancer indications, combining personalized medicine with companion diagnostics. It develops and commercia …
  • Flex Ltd.:企業の戦略・SWOT・財務分析
    Flex Ltd. - Strategy, SWOT and Corporate Finance Report Summary Flex Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Skyhawk Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Skyhawk Therapeutics Inc (Skyhawk) is a biotechnology company that discovers, develops and commercializes small molecule medicines that correct RNA expression. The company harnesses its STAR (Small molecule Therapies for Alternative splicing in RNA) platform, which combines information from …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆